The Medacta International AMIStem-P Post-Marketing Surveillance Study

• AMIStem-P (Device): Performance of Total Hip Arthroplasty (THA) with AMIStem-P femoral stem implant

Primary outcomes

• Survival rate [10 years]: Kaplan Meier method

Secondary outcomes

• Harris Hip Score [3/6 months, 1, 3, 5 and 10 years]: Harris Hip Score \[min = 0 (worst clinical outcome), max = 100 (best clinical outcome)\]
• Oxford Hip Score [3/6 months, 1, 3, 5 and 10 years]: Oxford Hip Score \[min = 0 (worst functional outcome), max = 48 (best functional outcome)\]
• Radiographic performance of the implants [3/6 months, 1, 3, 5 and 10 years]: Presence of radiolucencies, migration, loosening, subsidence, tilt
• Quality of life - Euroqol questionnaire [3/6 months, 1, 3, 5 and 10 years]: EQ-5D-5L score \[min = -0.59 (worst functional outcome), max = 1 (best functional outcome)\]
• Adverse events [intraop, 3/6 months, 1, 3, 5 and 10 years]: Intraoperative and postoperative adverse events

Sex: All, ages: 18 Years to 85 Years

Inclusion Criteria:

* Patients with a disease (primary coxarthrosis, inflammatory arthritis of the hip, necrosis of the femoral head, etc.) requiring a total hip replacement
* Patient eligible to receive an uncemented AMIStem-P femoral stem
* Patient agreeing to comply with the study requirements
* Patient willing to provide written informed consent
* Patient affiliated to a social security system
* Patients between 18 and 85 years old

Exclusion Criteria:

* Participation in biomedical research
* Patients younger than 18 years old
* Vulnerable adult patients according to article L1121-6 of the French Public Health Code
* Pregnant or breastfeeding women
* Patients unable to provide written informed consent

• Alexandru Nebunescu-Schirliu, MD, Principal investigator, Hôpital Jacques-Puel